Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 3 (2006), Issue 1 (January)

1. Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity.
   Eur Respir J, 27(1): 230-2. [Abstract] [Full-text]
2. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.
   Oncogene, 25(1): 147-51. [Abstract] [Full-text]
3. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
   Cancer Res, 66(1): 473-81. [Abstract] [Full-text]
4. Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer.
   Clin Cancer Res, 12(1): 152-8. [Abstract] [Full-text]
5. Induction of gastric GIST in rat and establishment of GIST cell line.
   Cancer Lett, 231(2): 295-303. [Abstract] [Full-text]
6. Pathology of gastrointestinal stromal tumors.
   Pathol Int, 56(1): 1-9. [Abstract] [Full-text]
7. Wnt/beta-catenin signaling mediates antineoplastic effects of imatinib mesylate (gleevec) in anaplastic thyroid cancer.
   J Clin Endocrinol Metab, 91(1): 159-68. [Abstract] [Full-text]
8. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.
   Blood, 107(2): 480-2. [Abstract] [Full-text]
9. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.
   Blood, 107(2): 752-9. [Abstract] [Full-text]
10. Chronic myeloid leukaemia and hairy cell leukaemia coexisting in a single patient: difficulties at diagnosis and rational of the therapeutic strategy.
    Leuk Res, 30(3): 349-53. [Abstract] [Full-text]
11. Functional integrity in vitro of hematopoietic progenitor cells from patients with chronic myeloid leukemia that have achieved hematological remission after different therapeutic procedures.
    Leuk Res, 30(3): 286-95. [Abstract] [Full-text]
12. Management of gastrointestinal stromal tumors in the imatinib era: selected case studies.
    Oncologist, 11(1): 9-20. [Abstract] [Full-text]
13. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma.
    Cancer, 106(2): 366-74. [Abstract] [Full-text]
14. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
    Cancer, 106(2): 346-52. [Abstract] [Full-text]
15. Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinoma.
    J Urol, 175(1): 53-6. [Abstract] [Full-text]
16. Immunohistochemical Analysis of Platelet-derived Growth Factor Receptor-alpha, -beta, c-kit, c-abl, and Arg Proteins in Glioblastoma: Possible Implications for Patient Selection for Imatinib Mesylate Therapy.
    J Neurooncol, 76(2): 105-9. [Abstract] [Full-text]
17. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.
    Trends Pharmacol Sci, 27(1): 17-24. [Abstract] [Full-text]
18. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
    J Clin Oncol, 24(3): 460-6. [Abstract] [Full-text]
19. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    J Clin Oncol, 24(3): 454-9. [Abstract] [Full-text]
20. Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
    Nat Chem Biol, 2(2): 95-102. [Abstract] [Full-text]
21. Targeted CML therapy: controlling drug resistance, seeking cure.
    Curr Opin Genet Dev, 16(1): 92-9. [Abstract] [Full-text]
22. Effects of imatinib mesylate (Glivec(R)) as a c-kit tyrosine kinase inhibitor in the guinea-pig urinary bladder.
    Neurourol Urodyn. [Abstract] [Full-text]
23. Continuous complete hematological and cytogenetic remission with molecular minimal residual disease 9 years after discontinuation of interferon-alpha in a patient with Philadelphia chromosome-positive chronic myeloid leukemia.
    Acta Haematol, 115(1): 109-12. [Abstract] [Full-text]
24. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.
    Cancer Res, 66(2): 1007-14. [Abstract] [Full-text]
25. MDCT appearance of gastrointestinal stromal tumors after therapy with imatinib mesylate.
    AJR Am J Roentgenol, 186(2): 510-5. [Abstract] [Full-text]
26. E2A and IRF-4/Pip promote chromatin modification and transcription of the immunoglobulin kappa locus in pre-B cells.
    Mol Cell Biol, 26(3): 810-21. [Abstract] [Full-text]
27. Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate.
    Clin Cancer Res, 12(2): 626-33. [Abstract] [Full-text]
28. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia.
    Blood Rev, 20(1): 29-41. [Abstract] [Full-text]
29. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
    Mutat Res, 603(1): 74-82. [Abstract] [Full-text]
30. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation.
    Leukemia, 20(2): 187-92. [Abstract] [Full-text]
31. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.
    Bioorg Med Chem Lett, 16(5): 1421-5. [Abstract] [Full-text]
32. Targeted therapy in colorectal cancer: do we know enough?
    Dig Liver Dis, 38(2): 71-7. [Abstract] [Full-text]
33. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Crit Rev Oncol Hematol, 57(2): 145-64. [Abstract] [Full-text]
34. Immunohistochemical and genetic features of gastric and metastatic liver gastrointestinal stromal tumors: Sequential analyses.
    Cancer Sci, 97(2): 127-32. [Abstract] [Full-text]
35. Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma.
    Invest New Drugs, 24(1): 85-8. [Abstract] [Full-text]
36. Female adnexal tumor of probable wolffian origin: Morphological, immunohistochemical, and ultrastructural study with c-kit gene analysis.
    Pathol Int, 56(2): 95-100. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.